Critical Limb Ischemia Treatment Market Size, Share, And Growth Report 2032

Critical Limb Ischemia Treatment Market: Size

The global Critical Limb Ischemia Treatment Market size was worth around USD 4.54 billion in 2023 and is predicted to grow to around USD 8.49 billion by 2032 with a compound annual growth rate (CAGR) of roughly 7.2% between 2024 and 2032.

The study provides historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue (USD billion). The report covers a forecast and an analysis of the Critical Limb Ischemia Treatment Market on a global and regional level.

Request Free Sample

Critical Limb Ischemia Treatment Market: Overview

Critical limb ischemia is a chronic disease of peripheral arteries, in which chronic inflammation allied with atherosclerosis causes abridged flow of blood and oxygen to the legs, hands, and feet. This, in turn, leads to chronic pain and soreness. The key factors responsible for critical limb ischemia disease include aging, as geriatric people are more susceptible to the development of these conditions, diabetes, obesity, extremely high cholesterol levels, sedentary lifestyle, smoking, and increased blood pressure. The common symptoms of critical limb ischemia disease are gangrene, ischemic rest pain, loss of tissue, etc.

The growing prevalence of critical limb ischemia is expected to drive the demand for its treatment, which, in turn, is predicted to propel the growth of the critical limb ischemia treatment market globally. In the U.S., about 2 to 3 million people are suffering from critical limb ischemia. Furthermore, the growing healthcare spending and increasing number of new drug development studies are also expected to boost the development of the critical limb ischemia treatment market globally. Additionally, the growing competition among the key players operating in the global critical limb ischemia market for the development of advanced therapy is anticipated to further propel the market growth in the future.

Critical Limb Ischemia Treatment Market: Segmentation

The study provides a decisive view of the global critical limb ischemia treatment market that is bifurcated based on treatment and region.

By treatment, the market is segmented into two major categories—devices and medications. On the basis of devices, the global critical limb ischemia treatment market includes peripheral dilatation systems, and embolic protection devices. The peripheral dilatation systems are further classified into vascular stents, and balloon dilators. The medications segment of the critical limb ischemia treatment market includes antihypertensive agents, antiplatelet drugs, antithrombotic agents, lipid-lowering agents, and others. In terms of growth rate, the critical limb ischemia devices segment is expected to register the highest CAGR in the global market over the forecasted time span.

Critical Limb Ischemia Treatment Market: Report Scope

Critical Limb Ischemia Treatment Market: Regional Analysis

The regional segment includes North America, Latin America, Asia Pacific, Europe, and the Middle East and Africa.

North American and European regions dominated the global critical limb ischemia treatment market with substantial market shares in the year 2023. This can be attributed to the high obesity rate, growing ischemia diseases due to unhealthy lifestyles across North America. The Asia Pacific region is expected to register the highest growth in the global critical limb ischemia treatment market in the years to come, owing to the increasing awareness among the regional population about the critical limb ischemia.

Critical Limb Ischemia Treatment Market: Competitive Players

Some major players of the global critical limb ischemia treatment market are:

• Boston Scientific Corporation
• Medtronic
• Cesca Therapeutics
• Pluristem Therapeutics
• Abbott Laboratories
• Rexgenero
• Micro Medical Solutions
• LimFlow
• Cardiovascular Systems

The Global Critical Limb Ischemia Treatment Market is segmented as follows:

Global Critical Limb Ischemia Treatment Market: Drug Type Analysis

• Devices
  • Embolic Protection Devices
  • Peripheral Dilatation Systems
    • Balloon Dilators
    • Vascular stents
• Medications
  • Antiplatelet Drugs
  • Antihypertensive Agents
  • Lipid-lowering Agents
  • Antithrombotic Agents
  • Others

Global Critical Limb Ischemia Treatment Market: Regional Analysis

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• Middle East and Africa